ClinicalTrials.gg

Program

LTG-001

A development code. Also written as “LTG-001 High Dose”, “LTG-001 Mid Dose” and “LTG-001 Low Dose”.

Its studies are mostly in Pain, Postoperative · Acute Pain, led by Latigo Biotherapeutics.

Furthest: phase 2, since Dec 23, 20244 company-led studies, 1 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Latigo Biotherapeutics41 open or runningphase 2since Dec 23, 2024Sep 15, 2023none ahead

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Sep 15, 2023First study: phase 1 study in HealthyFirst studyNCT06049095 · 204 enrolled · New Zealand
  2. Dec 23, 2024Phase 2 study in Pain, PostoperativeNCT06774625 · 250 enrolled · United States
  3. Jul 28, 2025Phase 2 study in Acute PainNCT07102459 · 343 enrolled · United States
  4. Dec 2, 2025Phase 1 study in AgnosiaNCT07341152 · 14 enrolled · United States

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 4 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07341152Agnosia · United States1CompletedNov 17, 202514
NCT07102459Acute Pain · United States2CompletedJan 7, 2026343
NCT06774625Pain, Postoperative · United States2CompletedAug 8, 2025250
NCT06049095Healthy · New Zealand1Active, not recruitingSep 2026204

How it is read

Names in the registry

  • “LTG-001”, 1 entry
  • “LTG-001 High Dose”, 1 entry
  • “LTG-001 Mid Dose”, 1 entry
  • “LTG-001 Low Dose”, 1 entry
  • “Experimental: LTG-001 High Dose”, 1 entry

Codes read as this program: LTG001.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.